Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities.
about
Developing Biosensors in Developing Countries: South Africa as a Case StudyMathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel TherapiesExtensively drug-resistant tuberculosis: epidemiology and managementFunctional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosisTuberculosis: epidemiology and controlEvaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel.Cost-effectiveness comparison of Genechip and conventional drug susceptibility test for detecting multidrug-resistant tuberculosis in ChinaLocked Nucleic Acid Probe-Based Real-Time PCR Assay for the Rapid Detection of Rifampin-Resistant Mycobacterium tuberculosisHigh mortality among tuberculosis patients on treatment in Nigeria: a retrospective cohort study.Acoustofluidic Transfer of Inflammatory Cells from Human Sputum SamplesUse of the Xpert(®) MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, ZambiaCytotoxic response persists in subjects treated for tuberculosis decades ago.The Bandim TBscore--reliability, further development, and evaluation of potential uses.Serological diagnostic assays for HIV-associated tuberculosis in sub-Saharan Africa?Modeling of novel diagnostic strategies for active tuberculosis - a systematic review: current practices and recommendations.Current trends and newer concepts on diagnosis, management and prevention of respiratory tract infections.'Cough officer' nurses in a general medical clinic successfully detect drug-susceptible and -resistant tuberculosis.Matrix-assisted laser desorption ionization-time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology.Identification of mycobacteria from solid and liquid media by matrix-assisted laser desorption ionization-time of flight mass spectrometry in the clinical laboratoryHost targeted activity of pyrazinamide in Mycobacterium tuberculosis infectionDrug-resistant tuberculosis in HIV-infected patients in a national referral hospital, Phnom Penh, Cambodia.The discovery and identification of a candidate proteomic biomarker of active tuberculosisA multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosismiRNA signatures in sera of patients with active pulmonary tuberculosisScreening and identification of six serum microRNAs as novel potential combination biomarkers for pulmonary tuberculosis diagnosis.Mycobacterial skin and soft tissue infection.Temporal Expression of Peripheral Blood Leukocyte Biomarkers in a Macaca fascicularis Infection Model of Tuberculosis; Comparison with Human Datasets and Analysis with Parametric/Non-parametric Tools for Improved Diagnostic Biomarker IdentificationRapid implementation of new TB diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF?Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda.RETROSPECTIVE STUDY OF MEASURING TUBERCULOSIS THERAPY COMPLIANCE: GREECE AS A HOST COUNTRY FOR VULNERABLE POPULATIONS BEFORE AND DURING THE FINANCIAL CRISISThe heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis.Validation of Mycobacterium tuberculosis Rv1681 protein as a diagnostic marker of active pulmonary tuberculosisAdvances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care testA metabolic biosignature of early response to anti-tuberculosis treatment.Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality.Interferon-Gamma Release Assay Performance of Cerebrospinal Fluid and Peripheral Blood in Tuberculous Meningitis in China.Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis.Economic evaluations of point of care testing strategies for active tuberculosis.Emerging technologies in point-of-care molecular diagnostics for resource-limited settings.Infections Caused by Mycobacterium tuberculosis in Recipients of Hematopoietic Stem Cell Transplantation.
P2860
Q26768606-5A2A7C6D-A560-4563-BFBD-1F48F747FD85Q26778117-42C93982-1574-4193-922B-C95E5A794CFAQ26830094-DDFB2BCF-1088-4931-9242-4ACD772FA999Q26849399-99696830-BCB9-4115-8AFB-ABF853FA4F7BQ27021104-9577F2AD-8C69-44B3-97BD-ABD27E6E03C0Q27690864-3FD13D2D-FDF2-42AA-A443-141807F15CA3Q28534773-F047A68E-0030-4E28-BF86-6BDFD7AAC83BQ28551104-7766804E-0660-4FF3-8F8C-9052C224B1AEQ30061805-5C2F34E3-8D7B-4711-9B7D-350201BFC4EBQ30354554-CDFC8D40-822E-4BD4-B4CE-77511BEAEE6CQ33593613-9AB209B6-E2C0-4EE4-912F-210BB9BBEA33Q33644223-7D11D862-993C-42C9-B271-333D3C29C670Q33655933-C66CAD1D-0115-4C9F-8D75-22D6BF6F0D4BQ33743476-61122E9F-20E2-4F47-9827-406A5EB9032AQ34395434-CF2E2521-DEE8-422B-A18F-634627F18B4BQ34465180-BD5A0393-6D46-4BE8-9A66-6CF00D92287DQ34482248-9555FA3A-3AC9-4639-AEDD-336FEB245567Q34653849-D60CB94A-BF81-4790-8AC9-68FEC7DB0CB6Q34785115-088879D2-0DBD-4359-98EE-1F68D55F6EA5Q34981779-79F03DCB-6E92-4199-980B-F80959E2C631Q35014534-A3937FD3-9B5B-43B1-8E17-CCD18FD49308Q35028192-7F64AE57-D286-46F7-9F6F-9C9D5ABDBDCBQ35042658-509F45CE-8051-40E7-8F75-C00B5DF9B9B0Q35053468-BE932B2C-97F2-4254-B11A-427C4C3A42CBQ35069484-7925AB32-7345-4DB4-82D0-A8474F36BADEQ35359858-4F4F3934-0DE2-4BFB-9342-A10284C30946Q36030652-0AC28A7D-93C6-4305-8181-3D1699FCE8E5Q36149564-254F1CB7-330D-4160-9E69-0D0EF96DED55Q36159840-197E2FBA-6765-4A12-ABA4-6CE9B79C4B65Q36264545-84D4D1DD-0BFB-45C5-BD65-108049BF84A3Q36675409-10CE49EA-9BC0-4207-B259-9AA42675BFC3Q36826688-495CDD5A-6B5D-455D-8697-3AC21D17B8FDQ36833723-C52AB9BA-4DAE-41ED-87A1-095333322D51Q37569320-90437FCB-26E0-4CB9-AA1A-F8C707AE7836Q37664997-01CEE8DC-64FE-4E5A-860F-7B89FFA24B34Q37681568-35887E86-FB91-4148-9359-F98419A411FBQ37682208-BE13594F-39C0-4070-8804-5154F5429F52Q38114142-F9E16C60-A565-4EA9-BC8E-745936E35F9EQ38208407-302B7326-4D64-4762-B3E8-6DEDA622D9BEQ38248018-581B2E3A-5BFB-478F-BB9F-DD9184047C28
P2860
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Tuberculosis diagnostics and b ...... t advances, and opportunities.
@en
type
label
Tuberculosis diagnostics and b ...... t advances, and opportunities.
@en
prefLabel
Tuberculosis diagnostics and b ...... t advances, and opportunities.
@en
P2093
P2860
P50
P356
P1476
Tuberculosis diagnostics and b ...... t advances, and opportunities.
@en
P2093
Ben Marais
Giovanni-Batista Migliori
Jeremiah Chakaya
Karin Weyer
Lucica Ditui
Marco Schito
Martina Casenghi
Michel Pletschette
Nathan Ford
Peter S Kim
P2860
P304
P356
10.1093/INFDIS/JIR860
P407
P478
205 Suppl 2
P50
P577
2012-04-10T00:00:00Z